Last reviewed · How we verify
Canephron® N
Canephron N is a herbal combination that reduces inflammation and supports kidney and urinary tract function through diuretic and antimicrobial properties.
Canephron N is a herbal combination that reduces inflammation and supports kidney and urinary tract function through diuretic and antimicrobial properties. Used for Acute and chronic urinary tract infections, Prevention of recurrent urinary tract infections, Supportive treatment of kidney and bladder conditions.
At a glance
| Generic name | Canephron® N |
|---|---|
| Sponsor | Bionorica SE |
| Drug class | Herbal combination / Phytopharmaceutical |
| Modality | Small molecule |
| Therapeutic area | Urology / Nephrology |
| Phase | Phase 3 |
Mechanism of action
Canephron N contains a standardized extract of three medicinal plants (Centaurii herba, Levistici radix, and Rosmarini folium) that work synergistically to promote urine flow, reduce urinary tract inflammation, and provide antimicrobial effects. The combination helps alleviate symptoms of urinary tract infections and supports overall renal health through its anti-inflammatory and diuretic mechanisms.
Approved indications
- Acute and chronic urinary tract infections
- Prevention of recurrent urinary tract infections
- Supportive treatment of kidney and bladder conditions
Common side effects
- Gastrointestinal upset
- Allergic reactions (rare)
- Photosensitivity (potential, due to Levistici radix)
Key clinical trials
- Safety and Efficacy of Canephron® N in the Management of Uncomplicated Urinary Tract Infections (uUTI) (PHASE3)
- Efficacy of CLR Compared to Fosfomycin Trometamol in Acute Lower uUTIs (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Canephron® N CI brief — competitive landscape report
- Canephron® N updates RSS · CI watch RSS
- Bionorica SE portfolio CI